Abstract Streptococcus pyogenes (Group A Streptococcus; GAS) is exquisitely adapted to
the human host, resulting in asymptomatic infection, pharyngitis, pyoderma, scarlet fever or …

Recent efforts have re-invigorated the Streptococcus pyogenes (Group A Streptococcus)
vaccine development field, though scientific, regulatory and commercial barriers persist, and …

Streptococcus pyogenes,(colloquially named “group A streptococcus”(GAS)), is a pathogen
of public health significance, infecting 18.1 million people worldwide and resulting in …

Adjuvants enhance the magnitude and the durability of the immune response to vaccines.
However, there is a paucity of comparative studies on the nature of the immune responses …

Streptococcus pyogenes, also known as Group A Streptococcus (GAS), is a Gram-positive
human-exclusive pathogen, responsible for more than 500 000 deaths annually worldwide …

Preclinical antigen discovery, vaccine formulation, and efficacy studies in animal models
have progressed significantly in recent years. There is now a need to move promising …

Streptococcus pyogenes causes at least 750 million infections and more than 500,000
deaths each year. No vaccine is currently available for S. pyogenes and the use of human …

Rheumatic heart disease (RHD) is a serious and long-term consequence of acute rheumatic
fever (ARF), an autoimmune sequela of a mucosal infection by Streptococcus pyogenes …

Background & Aims We recently developed a heterologous therapeutic vaccination scheme
(TherVacB) comprising a particulate protein prime followed by a modified vaccinia-virus …

Background Streptococcus pyogenes is a leading cause of infection-related morbidity and
mortality. A reinvigorated vaccine development effort calls for new clinically relevant human …